[go: up one dir, main page]

DK1815014T3 - Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons - Google Patents

Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons

Info

Publication number
DK1815014T3
DK1815014T3 DK05821698.7T DK05821698T DK1815014T3 DK 1815014 T3 DK1815014 T3 DK 1815014T3 DK 05821698 T DK05821698 T DK 05821698T DK 1815014 T3 DK1815014 T3 DK 1815014T3
Authority
DK
Denmark
Prior art keywords
breast cancer
prediction
molecular indicators
treatment response
likelihood
Prior art date
Application number
DK05821698.7T
Other languages
English (en)
Inventor
Joffre B Baker
John L Bryant
Soonmyung Paik
Steven Shak
Original Assignee
Genomic Health Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Nsabp Foundation Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK1815014T3 publication Critical patent/DK1815014T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
DK05821698.7T 2004-11-05 2005-11-04 Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons DK1815014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62544204P 2004-11-05 2004-11-05
PCT/US2005/039970 WO2006052731A2 (en) 2004-11-05 2005-11-04 Molecular indicators of breast cancer prognosis and prediction of treatment response

Publications (1)

Publication Number Publication Date
DK1815014T3 true DK1815014T3 (da) 2012-06-18

Family

ID=36337021

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05821698.7T DK1815014T3 (da) 2004-11-05 2005-11-04 Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons

Country Status (10)

Country Link
US (2) US7622251B2 (da)
EP (1) EP1815014B1 (da)
JP (1) JP4939425B2 (da)
AT (1) ATE550440T1 (da)
AU (1) AU2005304878B2 (da)
CA (1) CA2585561C (da)
DK (1) DK1815014T3 (da)
ES (1) ES2384107T3 (da)
IL (1) IL182930A (da)
WO (1) WO2006052731A2 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2261369T3 (da) * 2002-03-13 2014-07-28 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK3170906T3 (da) * 2003-06-24 2018-11-05 Genomic Health Inc Forudsigelse af sandsynligheden for tilbagefald af kræft
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1836629B1 (en) * 2004-11-05 2020-03-04 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1824340A4 (en) * 2004-12-17 2009-08-05 Bionovo Inc PROCESS FOR USING EXTRACTS OF SPECIES OF THE GENUS EPIMEDIUM
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
EP1873258A1 (en) 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in breast cancer
DK2081950T3 (da) * 2006-09-21 2013-06-03 Nuclea Biomarkers Llc Med irinotecanbehandling forbundne ekspressionsprofiler
EP3135773A1 (en) * 2006-09-27 2017-03-01 Sividon Diagnostics GmbH Methods for breast cancer prognosis
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
WO2008049953A1 (es) 2006-10-23 2008-05-02 Neocodex, S.L. Método de pronóstico y/o diagnóstico in vitro de hipersensibilidad a estrógenos o a sustancias con actividad estrogénica
US8470534B2 (en) * 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
US20090070138A1 (en) * 2007-05-15 2009-03-12 Jason Langheier Integrated clinical risk assessment system
WO2008145125A1 (en) * 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
CA2696304A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Estrogenic extracts of ligustrum lucidum ait. of the oleaceae family and uses thereof
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US20100317001A1 (en) * 2007-09-05 2010-12-16 Laurentian University Method of using tumour rna integrity to measure response to chemotherapy in cancer patients
AU2008296072A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Astragalus membranaceus Fisch.Bge.Var.mongolicus Bge. of the Leguminosae Family and uses thereof
US9155770B2 (en) * 2007-09-07 2015-10-13 Bionovo, Inc. Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof
EP2203178A4 (en) * 2007-09-07 2012-03-21 Bionovo Inc ESTROGENEXTRACTS FROM PUERARIA LOBATA WILLD, OHWI FROM THE FAMILY OF LEGUMINOSAE AND APPLICATIONS THEREOF
EP2194998A4 (en) * 2007-09-07 2012-03-21 Bionovo Inc STROGENIC EXTRACTS OF ASPARAGUS CONCHINCHINENSIS (LOUR.) MERR OF THE LILIACEAE FAMILY AND USES THEREOF
WO2009067553A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
US8512961B2 (en) * 2007-11-19 2013-08-20 Bionovo, Inc. Methods of detecting and treatment of cancers using Scutellaria barbata extract
AU2008329902A1 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata D. Don
US20090130118A1 (en) * 2007-11-19 2009-05-21 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
EP2065474A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
EP2065473A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic success in gynecologic cancer
EP2215251A2 (en) 2007-11-30 2010-08-11 Siemens Healthcare Diagnostics GmbH Method for predicting therapy responsiveness in basal like tumors
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
JP2011516583A (ja) * 2008-04-14 2011-05-26 バイオノボ・インコーポレーテッド エストロゲン受容体β介在疾患の治療のためのカリコシン及びその類似物質
US20090270273A1 (en) * 2008-04-21 2009-10-29 Complete Genomics, Inc. Array structures for nucleic acid detection
CA2723403A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
AU2009256028A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositons
US20090312437A1 (en) * 2008-06-06 2009-12-17 Bionovo, Inc., A Delaware Corporation Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
EP2340027A4 (en) * 2008-09-03 2012-04-04 Bionovo Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5550060B2 (ja) * 2008-10-03 2014-07-16 独立行政法人産業技術総合研究所 そうか病病原菌種のｐｃｒ定量用試薬キット
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20110195995A1 (en) * 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
ES2343996B1 (es) 2008-12-11 2011-06-20 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Metodo para la subclasificacion de tumores.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2010129343A2 (en) * 2009-04-28 2010-11-11 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
EP2425015B1 (en) 2009-04-29 2018-01-10 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US20100311601A1 (en) * 2009-05-01 2010-12-09 Nuvera Biosciences, Inc. Index of genomic expression of estrogen receptor (er) and er-related genes
EP2253715A1 (en) * 2009-05-14 2010-11-24 RWTH Aachen New targets for cancer therapy and/or diagnosis
JP5940517B2 (ja) 2010-03-31 2016-06-29 ジヴィドン ダイアグノスティックス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内分泌治療下における乳癌再発を予測するための方法
EP2591126B1 (en) 2010-07-07 2020-12-30 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
KR101857462B1 (ko) 2010-08-13 2018-05-14 소마로직, 인크. 췌장암 바이오마커 및 그것의 용도
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
RU2486518C1 (ru) * 2012-01-10 2013-06-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ прогнозирования возникновения местных рецидивов в послеоперационном рубце при уницентрическом инвазивном протоковом раке молочной железы у больных с сохраненной менструальной функцией
US11031096B2 (en) 2012-04-24 2021-06-08 Rna Diagnostics Inc. Method for determining efficacy of chemotherapy treatment for a subject
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10385400B2 (en) 2012-12-03 2019-08-20 Rna Diagnostics Inc. Methods and kits for monitoring response to radiation therapies in cancer
EP2951317B1 (en) 2013-02-01 2017-10-11 Sividon Diagnostics GmbH Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
US10731222B2 (en) 2013-10-04 2020-08-04 Rna Diagnostics Inc. RNA disruption assay for predicting survival
EP2910645A1 (en) * 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
EP3623482A1 (en) 2014-05-13 2020-03-18 Myriad Genetics, Inc. Gene signatures for cancer prognosis
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
CA2951514C (en) 2014-06-18 2025-09-09 Clear Gene, Inc. METHODS, COMPOSITIONS AND DEVICES FOR THE RAPID ANALYSIS OF BIOLOGICAL MARKERS
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
CA3008273A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
EP3679160A4 (en) 2017-09-08 2021-05-19 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
US12008747B2 (en) * 2019-07-29 2024-06-11 Case Western Reserve University Population-specific prediction of prostate cancer recurrence based on stromal morphology features
CN111500724B (zh) * 2020-04-28 2023-11-21 启程医学科技(山东)有限公司 用于乳腺癌六基因同时检测的引物组与探针组合
WO2023081988A1 (pt) * 2021-11-09 2023-05-19 Coelho Guilherme Portela Método para predição de eficácia de tratamento para câncer de mama

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
AU736587B2 (en) 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2330929A1 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
EP1218394A4 (en) 1999-10-06 2004-04-14 Univ California DIFFERENTIAL EXPRESSION GENES ASSOCIATED WITH OVER-EXPRESSION OF HER-2 / NEU
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (en) 2000-01-28 2006-04-05 Althea Technologies Inc METHOD FOR THE ANALYSIS OF GENE EXPRESSION
CA2393002A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001075159A2 (en) 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03000575A (es) 2000-07-21 2004-12-13 Global Genomics Ab Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
AU2001278011A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
WO2002046467A2 (en) 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
EP1350114A2 (en) 2001-01-12 2003-10-08 Yale University Detection of survivin in the biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
KR20030094281A (ko) 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
AU2002316251A1 (en) 2001-06-18 2003-01-02 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
EP1444361A4 (en) 2001-09-28 2006-12-27 Whitehead Biomedical Inst CLASSIFICATION OF PULMONARY CARCINOMAS BY ANALYSIS OF GENE EXPRESSION
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
DK2261369T3 (da) 2002-03-13 2014-07-28 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
AU2003215460A1 (en) 2002-03-28 2003-10-13 Qlt Inc. Cancer associated protein kinases and their uses
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
CA2848463A1 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy

Also Published As

Publication number Publication date
ATE550440T1 (de) 2012-04-15
AU2005304878A1 (en) 2006-05-18
CA2585561A1 (en) 2006-05-18
US7622251B2 (en) 2009-11-24
EP1815014B1 (en) 2012-03-21
EP1815014A2 (en) 2007-08-08
ES2384107T3 (es) 2012-06-29
JP4939425B2 (ja) 2012-05-23
IL182930A (en) 2013-03-24
AU2005304878B2 (en) 2010-07-08
US20060166231A1 (en) 2006-07-27
JP2008518620A (ja) 2008-06-05
CA2585561C (en) 2018-07-17
US20100184041A1 (en) 2010-07-22
IL182930A0 (en) 2007-09-20
WO2006052731A3 (en) 2007-04-19
WO2006052731A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
DK1815014T3 (da) Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons
Dong et al. Upregulation of long non-coding RNA small nucleolar RNA host gene 12 contributes to cell growth and invasion in cervical cancer by acting as a sponge for MiR-424-5p
Shi et al. Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer
Yu et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome
Heinzle et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis
Xu et al. Increased expression of circular RNA circ_0005230 indicates dismal prognosis in breast cancer and regulates cell proliferation and invasion via miR-618/CBX8 signal pathway
Ahn et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients
Dowsett et al. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer
Huang et al. Epigenetics in breast cancer: what's new?
Costa et al. Association between functional EGF+ 61 polymorphism and glioma risk
Bhandari et al. ITGA7 functions as a tumor suppressor and regulates migration and invasion in breast cancer
Chen et al. Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells
Wang et al. Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer
Hu et al. Long noncoding RNA EGFR-AS1 promotes cell proliferation by increasing EGFR mRNA stability in gastric cancer
Ibusuki et al. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients
Lv et al. Overexpression of lymphocyte antigen 6 complex, locus E in gastric cancer promotes cancer cell growth and metastasis
Wu et al. LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1
Nie et al. Prognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer
Qiu et al. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle
Yu et al. LncRNA SNHG16 promotes non‐small cell lung cancer development through regulating EphA2 expression by sponging miR‐520a‐3p
Zhang et al. MiR-940 promotes malignant progression of breast cancer by regulating FOXO3
Ma et al. TPX2 promotes cell proliferation and migration via PLK1 in OC
Zhao et al. Single-cell RNA-sequencing portraying functional diversity and clinical implications of IFI6 in ovarian cancer
Nikolić et al. Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population
Wang et al. A variant (rs932335) in the HSD11B1 gene is associated with colorectal cancer in a Chinese population